| |
Learn de-risking strategies in our whitepaper and explore the future of precision treatments from our survey of 100+ oncology professionals.
|
|
Today’s Big NewsOct 17, 2024 |
|
Gene and cellular therapies hold the extraordinary potential to transform
global health care. Download the QPS White Paper to explore the 5 critical
criteria to consider when choosing the best CRO for your next cell and gene
therapy development program.
|
|
| By Fraiser Kansteiner In a court decision filed in Washington, D.C., U.S. District Judge Dabney Friedrich rejected Novartis’ position that the FDA’s approval of MSN’s Entresto generic was unlawful. In issuing the decision, the judge upheld the green light that MSN won in July. Novartis has pledged to appeal the outcome. |
|
|
|
By James Waldron Sage Therapeutics’ latest attempt to shrink its pipeline and workforce will see a third of the biotech’s employees heading for the exits along with a swath of the company’s leadership. |
By Conor Hale At a town hall featuring FDA leadership at the AdvaMed MedTech Conference in Toronto, Michelle Tarver took the time to introduce—or reintroduce—herself to members of the industry, this time as the acting director of the agency’s Center for Devices and Radiological Health. |
By Zoey Becker The 24-hour Parkinson's disease therapy crossed the FDA finish line after an initial manufacturing-related rejection last year and another snub in June. |
|
Wednesday, October 23, 2024 | 11am ET / 8am PT Large, deeply characterized patient cohorts are one of the most promising data resources today for understanding disease biology and developing new medicines. Join us as we explore how this data is driving the next generation of pharmaceutical development. Learn how to leverage genetic research in today's highly competitive landscape. Register now.
|
|
By Darren Incorvaia With its lead candidate in a phase 3 trial for a rare eye cancer, Aura Biosciences is looking to expand the drug into a more common disease: bladder cancer. |
By Andrea Park Though psoriasis affects people of all skin tones, that diversity isn’t always represented in portrayals of the condition in clinical studies, commercials, textbooks and beyond. |
By Gabrielle Masson Terray Therapeutics has raked in $120 million for a series B fundraise as the AI-focused biotech aims to transform small molecule drug development. |
By Fraiser Kansteiner Viatris is ponying up $25 million upfront to obtain the rights to sell Lexicon Pharmaceuticals’ SGLT1/SGLT2 heart med sotagliflozin, known commercially as Inpefa, in all global markets beyond the U.S. and Europe. |
By Andrea Park As the first treatment cleared by the FDA for Demodex blepharitis, an eye disease estimated to affect 25 million people in the U.S. alone, Tarsus Pharmaceuticals’ Xdemvy is pitting its might against the skin-infesting mites that cause the disease. |
By Kevin Dunleavy With the clade 1 outbreak of mpox raging through parts of Africa, interim results of an NIH trial of Bavarian Nordic's Jynneos indicate that it is safe and elicits an immune response in adolescents. |
By Nick Paul Taylor Eli Lilly has thrown its weight behind a cause beyond the traditional remit of pharma companies. As the sponsor of an app for finding public restrooms, the Big Pharma is shining a light on just how common a problem finding the facilities is for people with ulcerative colitis. |
By Nick Paul Taylor Novartis is paying Chengdu Baiyu Pharmaceutical $70 million to add to its crop of cancer candidates. The deal, which features $1.1 billion in milestones, covers the global rights to a small molecule discovered by a Chinese biotech that has built a business around botanical drugs. |
By Nick Paul Taylor The more healthcare professionals know the pharma industry, the more they trust the pharma industry. That is the claim of U.K. pharma industry group ABPI, which reported another small uptick in how many HCPs trust drugmakers in its latest survey. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," Fierce Pharma's Fraiser Kansteiner chats with industry leaders about the surge in neuroscience investment, breakthroughs and future targets in neuropharmaceuticals. |
|
|---|
|
|
|
Thursday, October 24, 2024 | 1pm ET / 10am PT We will explore how incorporating comprehensive genetic services, like genetic testing access programs and clinical trial matching services, can increase identification of patients who meet program-specific inclusion/exclusion criteria, helping more patients benefit from life-changing therapeutics. Register today!
|
|
| eBookNeed the superpowers to select the right lab equipment? Sponsored by: PHC Corporation of North America |
| WhitepaperTake a brief journey through some of the efforts that Lonza has made to optimize the manufacturability of bsAbs and other formats, and take a glance towards future directions with an emphasis on the upstream aspects. Sponsored by: Lonza |
| WhitepaperHow can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter |
| WhitepaperUnlock the Future of Biotherapeutics with Catalent Biologics! Sponsored by: Catalent Biologics |
| WhitepaperFinding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner. Sponsored by: IQVIA |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
